Connell Consulting
HealthInvestor Awards 2015 Finalists
Remember me:
Skip Navigation Links
Axis-Shield resists new Alere takeover attempt

UK-based diagnostics company Axis-Shield has urged shareholders to resist a fresh takeover attempt by US rival Alere.

In a statement today, Alere repeated its offer to Axis-Shield’s shareholders of 460 pence per share, which was formally made on 5 August. The offer, rejected by the Axis-Shield board, values the business at £230 million.

Alere announced today that it is lowering the threshold of its bid, which had been set at 90% of shareholder acceptance. The company said it now required more than 50% of voting rights, giving it the option of becoming a majority shareholder in Axis-Shield.

The US company also warned that if its offer were to lapse by a deadline of 10 October, “there is a strong possibility that Axis-Shield's share price would fall significantly below its current share price, particularly as no other potential bidder has announced its interest publicly”.

Alere said it was also looking at “alternative acquisitions, particularly in light of current valuations and market conditions”, and that it didn’t necessarily have to acquire Axis-Shield in order to achieve its “strategic objectives”.

In response, Axis-Shield’s board said it was “disappointed” that Alere had not taken notice of the “firm rebuttal” from shareholders to its offer, which it said was clear by the less than 1% level of acceptances that was disclosed in an Alere announcement on 16 September.

“The board has been more than willing to engage with Alere if Alere were to put a proposal to the board that fairly reflected the fundamental value of Axis-Shield. To date, no such proposal has been received from Alere,” said an Axis-Shield statement.

“The company has made excellent progress in the first half of the year and is on track to deliver for the second half of the year. The company believes that Alere is making a highly opportunistic offer in order to try and acquire Axis-Shield on the cheap.”

The 460 pence per share offer price represents a premium of 37% on the closing share price of 335 pence on 5 July 2011 – the last business day before Alere revealed it was considering an approach.

Posted on: 26/09/2011

Latest news stories

Care services provider CareTech has raised £21 million in a funding round through the placing of 10 million shares at 210 pence each.
Japanese firm Nikon, which is most well-known for the cameras it produces, has agreed to acquire Optos for £259 million.
Public Accounts Committee chair Margaret Hodge has said that initial planning for the Better Care Fund was “deeply flawed”.
Primary Health Properties has been contracted to fund the development of and acquire two medical centres in Wales.
Octopus Healthcare is funding an Ashford-based £30 million private hospital.

HealthInvestor Asia - financial intelligence for Asia's healthcare markets

Buying and selling companies can be painful – for both parties. Ploy Radford examines the different steps management should take to secure a successful sale
Circle’s decision to walk away from Hinchingbrooke is shrouded in politics, conflicting assessments, rancour and intrigue. Whatever the truth of the matter, argues Vernon Baxter, there’s no escaping it’s a major setback for the independent sector
McCarthy & Stone had a bad recession, but after a recapitalisation it now plans to double the business. Sunniva Davies-Rommetveit finds out more

Christie + Co
Health technology start-up HearToday is winning backers to help it create affordable and easily portable audiometers
Sovereign Capital has made its first foray into the staffing market with Nurse Plus, but the deal is not just an agency play for the PE house
McCarthy & Stone had a bad recession, but after a recapitalisation it now plans to double the business. Sunniva Davies-Rommetveit finds out more
Clare Connell of Connell Consulting investigates the growing demand for investment in early-onset dementia services
Sir Stephen Bubb’s report has upped the pressure to move more autism and LD care provision into the community. What will his demands mean for independent providers, asks Ploy Radford

Click here to search all feature articles